ES2169783T3 - Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2. - Google Patents
Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.Info
- Publication number
- ES2169783T3 ES2169783T3 ES96117245T ES96117245T ES2169783T3 ES 2169783 T3 ES2169783 T3 ES 2169783T3 ES 96117245 T ES96117245 T ES 96117245T ES 96117245 T ES96117245 T ES 96117245T ES 2169783 T3 ES2169783 T3 ES 2169783T3
- Authority
- ES
- Spain
- Prior art keywords
- tolerance
- xenoinjertos
- aloinjertos
- administration
- improve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PROTEINA QUE UNE CD2, QUE ES UN DERIVADO DE UN POLIPEPTIDO LFA3 SOLUBLE, SIENDO EL DERIVADO UNA FUSION DE INMUNOGLOBULINA QUE INCLUYE EL POLIPEPTIDO LFA-3 FUSIONADO CON UNA ZONA DE INMUNOGLOBULINA, O ESTANDO EL POLIPEPTIDO LFA-3 SOLUBLE UNIDO A UN AGENTE FARMACEUTICO, Y QUE SE UTILIZA EN LA PREPARACION DE UN MEDICAMENTO PARA UTILIZAR EN UN METODO DE MEJORAR LA TOLERANCIA DEL TEJIDO ALOINJERTADO O XENOINJERTADO TRASPLANTADO EN UN MAMIFERO, INCLUYENDO UN SER HUMANO, DE FORMA QUE EL METODO INCLUYE EL IMPLANTE EN EL MAMIFERO DE UN ALOINJERTO O XENOINJERTO Y LA ADMINISTRACION DE LA PROTEINA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77270591A | 1991-10-07 | 1991-10-07 | |
US85070692A | 1992-03-12 | 1992-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2169783T3 true ES2169783T3 (es) | 2002-07-16 |
Family
ID=27118640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96117245T Expired - Lifetime ES2169783T3 (es) | 1991-10-07 | 1992-10-06 | Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2. |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0786255B1 (es) |
JP (2) | JPH07502495A (es) |
AT (1) | ATE210454T1 (es) |
AU (1) | AU678141B2 (es) |
CA (1) | CA2120731C (es) |
DE (1) | DE69232295T2 (es) |
DK (1) | DK0786255T3 (es) |
ES (1) | ES2169783T3 (es) |
WO (1) | WO1993006852A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0607332B1 (en) * | 1991-10-07 | 1997-12-17 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
EP0749323B1 (en) * | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
AU2006202939B2 (en) * | 1994-03-08 | 2008-11-20 | Dana-Farber Cancer Institute, Inc. | Methods of modulating T cell unresponsiveness |
US6001651A (en) * | 1998-03-20 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of LFA-3 |
HUP0103563A3 (en) * | 1998-08-31 | 2004-04-28 | Biogen Idec Ma Inc Cambridge | Method of modulating memory effector t-cells and compositions |
SI1109570T1 (sl) * | 1998-08-31 | 2006-04-30 | Biogen Idec Inc | Modulacija spominskih efektorskih T-celic z vezavnim sredstvom CD2 |
AU2980900A (en) | 1999-02-04 | 2000-08-25 | General Hospital Corporation, The | Methods for human allografting |
CA2454618C (en) | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
WO2005115436A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
EP3774863A1 (en) * | 2018-03-29 | 2021-02-17 | Pfizer Inc | Lfa3 variants and compositions and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260880A3 (en) * | 1986-09-11 | 1990-03-07 | Dana-Farber Cancer Institute, Inc. | Turning on of cytotoxicity |
CA1326940C (en) * | 1987-02-26 | 1994-02-08 | Michael Dustin | Purification of lfa-3 |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5185441A (en) * | 1988-08-26 | 1993-02-09 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3 |
WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
WO1991011194A1 (en) * | 1990-01-24 | 1991-08-08 | Biogen, Inc. | Lfa-3 as a vaccine adjuvant |
US5547853A (en) * | 1991-03-12 | 1996-08-20 | Biogen, Inc. | CD2-binding domain of lymphocyte function associated antigen 3 |
EP0607332B1 (en) * | 1991-10-07 | 1997-12-17 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
-
1992
- 1992-10-06 AT AT96117245T patent/ATE210454T1/de active
- 1992-10-06 DK DK96117245T patent/DK0786255T3/da active
- 1992-10-06 EP EP96117245A patent/EP0786255B1/en not_active Expired - Lifetime
- 1992-10-06 ES ES96117245T patent/ES2169783T3/es not_active Expired - Lifetime
- 1992-10-06 EP EP92922682A patent/EP0607353A1/en not_active Ceased
- 1992-10-06 AU AU28891/92A patent/AU678141B2/en not_active Ceased
- 1992-10-06 JP JP5507247A patent/JPH07502495A/ja active Pending
- 1992-10-06 DE DE69232295T patent/DE69232295T2/de not_active Expired - Lifetime
- 1992-10-06 WO PCT/US1992/008754 patent/WO1993006852A2/en not_active Application Discontinuation
- 1992-10-06 CA CA002120731A patent/CA2120731C/en not_active Expired - Fee Related
-
2002
- 2002-07-25 JP JP2002216736A patent/JP2003128579A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH07502495A (ja) | 1995-03-16 |
EP0607353A1 (en) | 1994-07-27 |
ATE210454T1 (de) | 2001-12-15 |
WO1993006852A2 (en) | 1993-04-15 |
AU2889192A (en) | 1993-05-03 |
EP0786255A1 (en) | 1997-07-30 |
JP2003128579A (ja) | 2003-05-08 |
CA2120731A1 (en) | 1993-04-15 |
DE69232295T2 (de) | 2002-07-18 |
DK0786255T3 (da) | 2002-04-15 |
WO1993006852A3 (en) | 1993-07-22 |
CA2120731C (en) | 2008-08-19 |
AU678141B2 (en) | 1997-05-22 |
EP0786255B1 (en) | 2001-12-12 |
DE69232295D1 (de) | 2002-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yoo et al. | Induction of arthritis in monkeys by immunization with type II collagen. | |
ES2169783T3 (es) | Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2. | |
ATE107514T1 (de) | Stabilisierte protein- oder peptidkonjugate. | |
ES2080838T3 (es) | Conjugados de anticuerpos especificos del receptor de transferrina y agentes neurofarmaceuticos. | |
BR9915852A (pt) | Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina | |
DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
UY23665A1 (es) | Procedimiento para la preparacion de compuesto farmaceutico | |
EP0330227A3 (en) | Derivatives of soluble t-4 | |
JPH01100133A (ja) | 包外摘出後の後水晶体包の混濁化を防止する有糸分裂抑制剤及び方法 | |
DK0621786T3 (da) | Induceret tolerance over for xenotransplantater | |
Rao et al. | Analysis of proteins of bovine lens, vitreous, and aqueous by electrophoresis and by Oudin's gel diffusion technique | |
EP0770680A3 (en) | Lymphocyte-associated cell surface protein | |
DE69013797D1 (de) | Gehirnspezifische Zubereitung mit gesteuerter Abgabe. | |
Gitlin et al. | The thymus and other lymphoid tissues in congenital agammaglobulinemia: II. Delayed hypersensitivity and homograft survival in a child with thymic alymphoplasia | |
AU5979201A (en) | Methods of blocking tissue destruction by autoreactive t cells | |
AU3757789A (en) | Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates | |
BR9509433A (pt) | Uso de (r-(z))-a-(metaxoiimino)-a-(1-azabiciclo-(2,2,2)oct-3-il)acetonitrila ou um sal farmaceuticamente aceitável da mesma processo para aperfeiçoar o processamento de uma proteina precursora de amilóide ao longo de um percurso não amiloidogênio processo para tratamento ou profilaxia do mal de alzheimer composição farmacêutica e uso processo ou composição | |
Kerwar et al. | Passive transfer of arthritis by purified anticollagen immunoglobulin: localization of 125I-labeled antibody | |
NO892015D0 (no) | Fremgangsmaate for fremstilling av et legemiddel. | |
PT89224A (pt) | Processo para a preparacao de peptidos para o bloqueamento da actividade do pai-1 no sangue humano e sua utilizacao na preparacao de anticorpos | |
PT92071A (pt) | Processo de preparacao de imunotoxinas e de preparados farmaceuticos para o tratamento ou profilaxia de doencas auto-imunes | |
Hyder et al. | Humoral responses to type I collagen after surgical curettage procedures employing bovine collagen implants | |
JPH05238941A (ja) | 薬剤組成物 | |
DE69322960T2 (de) | Empfängnisverhütender impfstoff | |
MJ | < A> specific gastric inhibitory polypeptide antiserum recognising a single molecular form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 786255 Country of ref document: ES |